Aceclidine-based Eye Drops Effective in Treating Presbyopia, reveals phase 3 trial

The recent press release from a prominent biopharmaceutical company, LENZ Therapeutics, Inc. unveiled promising findings from its Phase 3 CLARITY study making a significant stride forward in the treatment of presbyopia. The study evaluated two formulations of aceclidine, LNZ100 and LNZ101 by demonstrating their potential to enhance the near vision in individuals with presbyopia.

Presbyopia is characterized by the gradual loss of near vision typically experienced by the individuals over 45 years and affects millions throughout the globe. This impacts the daily activities like reading and close-up work. The breakthrough of LENZ involves the development of aceclidine-based eye drops to reduce the effects of this condition to alternate the traditional corrective aids like reading glasses.

The Phase 3 trials comprised CLARITY 1 and 2 that showed compelling efficacy and safety profiles for LNZ100 with statistically significant improvements in Best Corrected Distance Visual Acuity (BCDVA) at near observed in the participants. Also, LNZ100 expressed rapid onset, sustained efficacy and reproducible near vision improvement across the diverse age groups and refractive ranges. Both LNZ100 and LNZ101 met primary and secondary endpoints, with LNZ100 emerging as the lead candidate due to its superior performance. Also, LNZ100 demonstrated a elevated responder rate and prolonged efficacy which garnered positive feedback from participants and investigators alike.